PIERIS - Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology - Gilde Healthcare

PIERIS – Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology

15. Juli 2008

FREISING-WEIHENSTEPHAN and JENA, Germany, July 16 /PRNewswire/ — Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, and Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, announced today a significant milestone in the development of Pieris’ PRS-050 Anticalin® for clinical trials.

Pieris has developed PRS-050 as a next generation VEGF antagonist and as the first Anticalin® -based product in its proprietary pipeline. PRS-050 exemplifies many of the favourable characteristics of Anticalins®: compact protein structure, high intrinsic stability, broad formulation flexibility and small molecular size improving the likelihood of effective target access. PRS-050 has already demonstrated potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as, anti-tumour activity and is expected to enter the clinic in 2009.

Wacker’s proprietary E. coli secretion system is a well-established technology for the cost-efficient production of proteins. At the core of the technology is a proprietary E. coli K12-strain, developed by Wacker, to secrete recombinant proteins in native form. Production of clinically relevant proteins via direct extracellular secretion offers a far more cost effective approach to biopharmaceutical product manufacture than traditional protein refolding technologies.

Andreas Hohlbaum Ph.D., Chief Technology Officer of Pieris, stated:

“Pieris has long-established expertise in small scale expression of Anticalins® for research use. As we progress our products to the clinic, we have established through our relationship with Wacker that an efficient production scale-up is possible. These excellent results and subsequent agreement with Wacker will expedite process development and GMP manufacture of Anticalins® for both proprietary and partnered products.”

Thomas Maier Ph.D., Managing Director of Wacker Biotech, commented further:

“The Anticalin® technology is one of the most exciting ‘Beyond Antibody’ technologies and we are very proud to support Pieris in its aims to develop this new class of therapeutic proteins. The results obtained to date underscore the power of our E. coli secretion technology and highlight Wacker Biotech’s commitment to becoming a leading force as a full-service contract manufacturer of biopharmaceuticals.”

More information on Pieris AG is available at http://www.pieris-ag.com
More information on Wacker Biotech GmbH is available at http://www.wacker.com/biologics

For further information, please contact:

Pieris AG
Andreas Hohlbaum PhD, Chief Technology Officer
Phone +49(0)8161-1411-400

Wacker Chemie AG
Press and Information
Nadine Baumgartl
Phone +49(0)89-6-2791-604

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
11. Juni 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
3. Juni 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
28. April 2025